|
Feb 13
|
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
|
|
Feb 12
|
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
|
|
Feb 12
|
Q4 2024 SAGE Therapeutics Inc Earnings Call
|
|
Feb 12
|
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
|
|
Feb 11
|
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 11
|
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
|
|
Nov 20
|
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
|
|
Nov 20
|
Sage’s string of research failures continues
|
|
Nov 20
|
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
|
|
Oct 17
|
Sage lays off 55% of R&D workforce and refocuses pipeline
|
|
Oct 17
|
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
|
|
Oct 17
|
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
|
|
Oct 17
|
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
|
|
Oct 17
|
Sage to cut one-third of workforce, streamline drug pipeline
|
|
Oct 17
|
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
|
|
Oct 15
|
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
|
|
Oct 10
|
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
|
|
Oct 9
|
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
|
|
Oct 8
|
Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
|
|
Oct 8
|
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
|